Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORY: Rosiglitazone for Prevention of Atherosclerosis Progression After CABG in Diabetic Patients
NCT00169832Phase 3Completed
- Sponsor
- Université Laval
- Start
- Jun 2003
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of rosiglitazone in atherosclerosis, sponsored by Université Laval. Started Jun 2003; status: completed.
02
Drugs
rosiglitazone
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00169832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169832.